Commentary

Filter By:

  • Digital medicine is poised to transform biomedical research, clinical practice and the commercial sector. Here we introduce a monthly column from R&D/venture creation firm PureTech tracking digital medicine's emergence.

    • Eric Elenko
    • Lindsay Underwood
    • Daphne Zohar
    Commentary
  • Analyzing structural similarities between compounds derived from traditional oriental medicine and human metabolites is a systems-based approach that can help identify mechanisms of action and suggest approaches to reduce toxicity.

    • Hyun Uk Kim
    • Jae Yong Ryu
    • Sang Yup Lee
    Commentary
  • Big pharma's storehouse of trouble has fostered consumer mistrust and a negative view of the industry. How does the industry go about restoring its flagging reputation?

    • Mark Kessel
    Commentary
  • The reliability of scientific research is under scrutiny. A recently convened working group proposes cultural adjustments to incentivize better research practices.

    • Marcus Munafò
    • Simon Noble
    • Robi Blumenstein
    Commentary
  • Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.

    • Troyen A Brennan
    • James M Wilson
    Commentary
  • Immunology is on the cusp of a 'big data'–driven breakthrough, but strategies for standardizing and sharing high-dimensional data from independent laboratories are needed to ensure that data support the formation of new and robust hypotheses.

    • Berend Snijder
    • Richard Kumaran Kandasamy
    • Giulio Superti-Furga
    Commentary
  • Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.

    • Jacob S Sherkow
    • Christopher Scott
    Commentary
  • Metabolic reconstructions remain limited in their scope and content, and improvements in biochemical knowledge and collaborative research are required.

    • Jonathan Monk
    • Juan Nogales
    • Bernhard O Palsson
    Commentary
  • Regulatory fallout from a scandal surrounding the fabrication of data used to support a molecular test in a Duke University cancer trial is exacting an unjustifiable toll not only on health economics but also on patient lives.

    • Razelle Kurzrock
    • Hagop Kantarjian
    • David J Stewart
    Commentary
  • Too few precompetitive consortia are being formed to mitigate lost opportunities and deliver on other potential mutual gains for public and private stakeholders in drug development.

    • Barbara Mittleman
    • Garry Neil
    • Joel Cutcher-Gershenfeld
    Commentary
  • Open collaboration on biomedical discoveries requires a fundamental shift in the traditional roles and rewards for both investigators and participants in research.

    • Stephen H Friend
    • Thea C Norman
    Commentary